NASAL

Chalmers University Pilot Project Developing Nasal spray to deliver vaccine against COVID-19

Chalmers University Pilot Project Developing Nasal spray to deliver vaccine against COVID-19

A unique concept for a nasal spray mRNA vaccine against covid-19 is being investigated in a new pilot project. The Swedish group is exploring design principles for nasal immunisation, developing a biomimetic nanoparticle provided with both immune enhancers and a targeting protein.

EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?

EU MDR DEADLINE DELAY: WHAT DOES IT MEAN FOR THE MEDICAL DEVICE INDUSTRY?

With the compliance deadline for the EU Medical Device Regulation recently delayed by a year due to the novel coronavirus pandemic, Beth Crandall looks at what it means for the medical device industry.

KEY NOSE CELLS IDENTIFIED AS LIKELY COVID-19 VIRUS ENTRY POINTS

KEY NOSE CELLS IDENTIFIED AS LIKELY COVID-19 VIRUS ENTRY POINTS

Researchers from the Human Cell Atlas Lung Biological Network, have identified two specific cell types in the nose as likely initial infection points for COVID-19 coronavirus, and cells in the eye and some other organs that also contain the viral-entry proteins. They also predict how a key entry protein is regulated with other immune system genes and reveals potential targets for the development of treatments to reduce transmission.

OPTIMISING NASAL DRUG PRODUCTS FOR SYSTEMIC DELIVERY

Intertek Pharmaceutical Services

OPTIMISING NASAL DRUG PRODUCTS FOR SYSTEMIC DELIVERY

David Ward discusses the benefits of systemic nasal delivery, describes a number of formulation strategies, and explains how to optimise absorption through properly informed formulation and device selection.

RETRONOSE: IMPROVING NASAL DELIVERY THROUGH A NEW AND IMPROVED DEVICE

Dr Laurent Vecellio

RETRONOSE: IMPROVING NASAL DELIVERY THROUGH A NEW AND IMPROVED DEVICE

Laurent Vecellio, Déborah Le Pennec, Guillaume Grevin and Alain Regard evaluate the performance of the RetroNose nasal drug delivery device.

THE IMPORTANCE OF TRAINING AND ONBOARDING FOR INTRANASAL RESCUE THERAPIES

THE IMPORTANCE OF TRAINING AND ONBOARDING FOR INTRANASAL RESCUE THERAPIES

With a recent resurgence in nasal drug repurposing, Joe Masci looks at the importance of training and onboarding for intranasal rescue therapies.

INNOVATIVE DRUG-ELUTING ADHESIVES: APPLICATION IN CHRONIC RHINOSINUSITIS

Dr Maria Pereira

INNOVATIVE DRUG-ELUTING ADHESIVES: APPLICATION IN CHRONIC RHINOSINUSITIS

Maria Pereira, Elise DeVries and Camille Legros introduce novel applications in the treatment of chronic rhinosinusitis for the company’s programmable synthetic polymers and an associated delivery device.

Inhaled and nasal Covid-19 vaccine progress

Inhaled and nasal Covid-19 vaccine progress

Specialist respiratory drug product news publication OINDP News, has reported progress from several intranasal and inhaled COVID-19 vaccine development programmes, including from Altimmune, APEPTICO, a partnership between Neurimmune and Ethris, and a partnership between UW–Madison, FluGen and Bharat Biotech.

BIOHAVEN GIVEN FDA GO-AHEAD TO BEGIN PHASE II TRIAL OF INTRANASAL VAZEGEPANT IN COVID-19 LUNG INFLAMMATION

BIOHAVEN GIVEN FDA GO-AHEAD TO BEGIN PHASE II TRIAL OF INTRANASAL VAZEGEPANT IN COVID-19 LUNG INFLAMMATION

Biohaven is to initiate a Phase II trial within weeks of intranasal vazegepant, its third-generation, high-affinity, selective small molecule CGRP receptor antagonist, in pulmonary complications of COVID-19 disease. The clinical trial will assess the potential benefits of CGRP receptor-blockade in mitigating an excessive immune response which in some cases can be fatal in COVID-19.

THE CURRENT STATE OF PLAY IN CONNECTED DEVICES

THE CURRENT STATE OF PLAY IN CONNECTED DEVICES

Marcus Bates; Joachim Koerner and Jerôme Prraquin discuss the current state of play, what connected device advocates are doing to enable faster implementation, and how we can optimise connected technology while reducing the cost and improving human factors.

PATIENT SAFETY: KEY DRIVER TO PRESERVATIVE-FREE NASAL SPRAY DEVELOPMENT

Benoit Guillard

PATIENT SAFETY: KEY DRIVER TO PRESERVATIVE-FREE NASAL SPRAY DEVELOPMENT

Benoît Guillard, Pascale Farjas and Audrey Chandra look at the effects of preservatives in nasal sprays, and the challenges and advantages of delivering preservative-free nasal spray drugs.

A FASTER, MORE COST-EFFECTIVE ALTERNATIVE TO GENERIC BIOEQUIVALENCE

A FASTER, MORE COST-EFFECTIVE ALTERNATIVE TO GENERIC BIOEQUIVALENCE

Jag Shur explores the challenges companies face in bringing generic respiratory and nasal therapies to market – and how some organisations have proactively addressed the challenge and developed services to integrate the device and the formulation, introducing the Aptar Pharma Services offering.

WHEN EVERY SECOND COUNTS…

WHEN EVERY SECOND COUNTS…

Todd Pizitz and Donald Mealing look at efforts to reduce the number of opioid-related deaths in the United States, and introduce a nasal device that delivers naloxone.

F2V: A STERILE, CUSTOMISABLE LIQUID FILL-FINISH PLATFORM FOR THE TOTAL LIFECYCLE

INDUSTRIALISATION

Simon Strothers

F2V: A STERILE, CUSTOMISABLE LIQUID FILL-FINISH PLATFORM FOR THE TOTAL LIFECYCLE

Simon Strothers presents an integrated fill-finish platform, F2V, designed to represent a commercial filling system as a bench-top solution. The article also includes a recent case study where the F2V was used by Consort Medical to help develop and industrialise a flagship delivery device.

CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL

CONNECTED DEVICES – MEDICATION DELIVERY JUST GOT PERSONAL

Thierry Decock and Hadrien Gremillet explore how the obstacles to the adoption of connectivity can be overcome and how connected devices can deliver truly patient-centric care that will clearly improve adherence rates, whilst demonstrating a clear cost benefit to the pharmaceutical partner.

BEST PRACTICES FOR DEVELOPING EFFECTIVE TRAINING DEVICES FOR PULMONARY HEALTHCARE

BEST PRACTICES FOR DEVELOPING EFFECTIVE TRAINING DEVICES FOR PULMONARY HEALTHCARE

Joe Reynolds discusses the current state of pulmonary drug delivery device trainers, including their value to patients, the complexities of modern design and the stringent quality requirements.

GUILLAUME BROUET, APTAR PHARMA

Guillaume Brouet

GUILLAUME BROUET, APTAR PHARMA

Guillaume Brouet talks with ONdrugDelivery Magazine about how Aptar Pharma uses its device development expertise and infrastructure to provide its pharmaceutical company customers a comprehensive services offering around device development, global regulatory approval and commercialisation.

THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT

THE CHALLENGES OF DELIVERING QBD IN NOVEL RESPIRATORY DEVELOPMENT

David Belton discusses the meaning of quality by design in novel respiratory drug delivery device development. He covers how, with more novel devices, prior knowledge may be insufficient for a standard FMEA-style risk analysis, and alternate science-based methods, such as functional mapping and knowledge scoring, can help in achieving QbD.

PAUL ALLSOP, MILES KOTTMAN, HANNAH PRIESTLY & JON REED, CONSORT GROUP

Bespak by Recipharm

PAUL ALLSOP, MILES KOTTMAN, HANNAH PRIESTLY & JON REED, CONSORT GROUP

Consort Medical's Paul Allsop, Miles Kottman, Hannah Priestly and Jon Reed talk with ONdrugDelivery Magazine about the company’s integrated formulation and device offering, and focus on its simple, low-cost, single unit-dose, spring powered nasal device, Unidose Xtra.

130 A DAY AND GROWING: ANSWERING THE US OPIOID OVERDOSE EPIDEMIC

130 A DAY AND GROWING: ANSWERING THE US OPIOID OVERDOSE EPIDEMIC

Todd Pizitz and Donald Mealing discuss the ongoing opioid crisis in the US and the current use of the opioid reversal medication naxalone, and introduce the CounterAct device for naxalone home use.

IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?

IS THERE A FUTURE FOR THE RESPIRATORY DELIVERY OF BIOLOGICS?

Igor Gonda covers the field of nasal and pulmonary delivery of biologics, considers past failures and successes, and proposes answers to the challenges faced, from biological, biopharmaceutical and commercial standpoints.

REDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION

Proveris Scientific

REDUCING VARIABILITY IN TEST RESULTS FOR OINDPS WITH AUTOMATED ACTUATION

Heli Chauhan and Linda (Lingzhi) Liao discuss the importance of automated actuation for testing inhalation and spray devices to avoid variability introduced by manual method.

NASAL DRUG DELIVERY VIA THE ORAL ROUTE USING A PMDI

Dr Laurent Vecellio

University of Tours

NASAL DRUG DELIVERY VIA THE ORAL ROUTE USING A PMDI

Laurent Vecellio, Déborah Le Pennec and Alain Regard, Technology Product Manage discuss a study Nemera has funded into the retronose concept, using a pMDI to deliver to the nasal cavity via the oral route during exhalation through the nose.

EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY

EXPANDING CONNECTIVITY: ADD-ONS FOR OPHTHALMIC AND NASAL DELIVERY

Nemera introduces the e-Novelia® and e-Advancia® add-ons for ophthalmic and nasal devices.

Prev
1
2
3
4
5
Next

Top